General Announcement::GPL receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
17-Jul-2018 12:37:49
Status
New
Announcement Sub Title
GPL receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension
Announcement Reference
SG180717OTHRU7EC
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
17/07/2018 10:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

Attachments

PR_17072018.pdf
Total size =3484K